Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Coronary Microvascular Angina
NCT06811831Phase 1Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of macitentan in microvascular angina (MVA), sponsored by China-Japan Friendship Hospital. Primary endpoints: Coronary Flow Reserve at 4 weeks and Index of Microcirculatory Resistance at 4 weeks. Started Nov 2024; status: recruiting.
02
Drugs
macitentan
03
Conditions
microvascular angina (MVA)
Beyond the preview
Go deeper on NCT06811831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811831.